PNAS scraps special submission

A leading scientific journal has done away with a manuscript submission option that allowed members of the National Academy of Sciences to usher papers from non-members through the peer review process. The __Proceedings of the National Academy of Sciences__ (__PNAS__) offered the option, called "Track I," to members of the Academy as a way to bring papers written by non-members to the journal's attention. Members were allowed to "communicate" two Track I papers per year, and were responsible fo

Written byBob Grant
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
A leading scientific journal has done away with a manuscript submission option that allowed members of the National Academy of Sciences to usher papers from non-members through the peer review process. The __Proceedings of the National Academy of Sciences__ (__PNAS__) offered the option, called "Track I," to members of the Academy as a way to bring papers written by non-members to the journal's attention. Members were allowed to "communicate" two Track I papers per year, and were responsible for procuring at least two reviews of the manuscript before submitting it to the __PNAS__ editorial office. Starting July 1, 2010, __PNAS__ will require non-members to submit manuscripts to the journal via the normal route, "Track II," according to linkurl:__ScienceInsider__.;http://blogs.sciencemag.org/scienceinsider/2009/09/the-academys-jo.html A paper submitted via this route is screened by a __PNAS__ editorial board member, who decides whether the paper is scientifically sound and likely to represent the top 10% of its field. If the paper passes muster, the board member hands it off to an Academy member for editing. "Since the introduction of Track II as the general route for submitted papers, many members will no longer communicate papers through Track I," wrote Alan Fersht, a __PNAS__ associate editor, in a 2005 linkurl:editorial;http://www.pnas.org/content/102/18/6241.full.pdf in the journal. But in 2009 __PNAS__ has published approximately 390 papers (about 12.5% of the total published) that were submitted using the Track I route, according to __ScienceInsider__. Researchers submitting papers to __PNAS__ will still be allowed to suggest referees and editors for their manuscripts. __Editor's Note (10th Sept.) - linkurl:Here;http://www.pnas.org/content/early/2009/09/08/0909515106.full.pdf+html?sid=b8e6becf-082b-4f07-bd96-c28143c850f3 is the __PNAS__ editorial that explains the decision to ditch Track I.__
**__Related stories:__***linkurl:Does It Pay To Know An Academy Member?;http://www.the-scientist.com/article/display/18006/
[13th April 1998]*linkurl:Editors' Advice To Rejected Authors: Just Try, Try Again;http://www.the-scientist.com/article/display/17713/
[15th September 1997]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies